



Tobin P. Sullivan

Principal

T +1 (617) 248-4742 | M +1 (508) 633-2075
tsullivan@choate.com

Tobin Sullivan is a versatile corporate and securities attorney who counsels growth equity and venture capital investors and growing life sciences and technology companies, ranging from start-ups to pre-IPO companies to global public companies, on a wide range of transactional and corporate law matters. With extensive experience in venture capital and late-stage, cross-over financings for life sciences, biotech and healthIT companies, he is described by clients as a highly responsive, strategic thinker who balances his strong market knowledge with practical business advice.

Tobin provides general corporate guidance on a variety of business matters, including venture capital and growth equity financings, national and cross-border mergers and acquisitions, corporate governance matters, public company reporting, and SEC compliance. His clients have included Bain Capital Life Sciences, Surveyor Capital (a Citadel company), Andreesen Horowitz, Sectoral Asset Management, Transformation Capital, Pegasystems, Forrester Research, Riverside Partners, Summit Partners, and M/C Partners.

PRACTICE AREAS

Business & Technology

Private Equity

Life Sciences

Emerging Companies

RECOGNITION

- *Massachusetts Super Lawyers* Rising Star

REPRESENTATIVE ENGAGEMENTS

Venture Capital & Private Equity Engagements:

- **Bain Capital Life Sciences'** growth equity investments in biotech companies, including:
 - **Arcutis Biotherapeutics** (*Nasdaq: ARQT*) - \$95 million Series C financing
 - **Aptinyx** (*Nasdaq: APTX*) - \$70 million Series B financing
 - **Atea Pharmaceuticals** - \$215 million Series D financing
 - **ViaCyte** - \$80 million Series D financing
 - **JenaValve Technology** - \$50 million private financing
- **Transformation Capital's** growth equity investments in Health IT and healthcare services companies.

EDUCATION

Northeastern University School
of Law

JD, 2012

Staff Member, *Northeastern
University Law Journal*

Cornell University
BS, 2007

ADMISSIONS

Massachusetts

Maine

- **Surveyor Capital's** cross-over and venture capital investments in life sciences companies, including:
 - **VelosBio** - \$137 million Series B financing
 - **Allogene** (*Nasdaq: ALLO*) - \$120 million private financing
 - **Zentalis Pharmaceuticals** (*Nasdaq: ZNTL*) - \$85 million Series C financing
 - **NextCure** (*Nasdaq: NXTC*) - \$93 million Series B financing
 - **Annexon Biosciences** (*Nasdaq: ANNX*) - \$100m Series D and \$75 million Series C financings
 - **SpringWorks Therapeutics** (*Nasdaq: SWTX*) - \$125 million Series B financing
 - **Satsuma Therapeutics** (*Nasdaq: STSA*) - \$62 million Series B financing
 - **AVROBIO** (*Nasdaq: AVRO*) - \$60 million Series B financing
 - **Gossamer Bio** (*Nasdaq: GOSS*) - \$230 million Series B financing
 - **Sutro Biopharma** (*Nasdaq: STRO*) - \$84 million Series E financing
 - **Akouos** (*Nasdaq: AKUS*) - \$105 million Series B financing
 - **ElevateBio** - \$170 million Series B financing
 - **Praxis Precision Medicines** - \$110 million Series C financing
 - **Pliant Therapeutics** - \$100 million Series C financing
 - **Bolt Biotherapeutics** - \$93.5 million Series C financing
 - **Athira Pharmaceuticals** - \$85 million Series B financing
 - **Spruce Biosciences** - \$88 million Series B financing
 - **Oncorus** - \$80 million Series B financing
- **Andreessen Horowitz's** venture capital investment in Ribbon Health.
- **M/C Partners'** carve-out acquisition of Ascend Technologies from West Monroe Partners.
- **Riverside Partners'** majority investment in 3Play Media.
- **Sectoral Asset Management's** growth equity investments in therapeutics companies, including:
 - **Apellis Pharmaceuticals** (*Nasdaq: APLS*) - \$60 million Series E financing
 - **Pipeline Therapeutics** - \$30 million Series B financing

Business & Technology Engagements:

- **Pegasystems Inc.'s** (*Nasdaq: PEGA*) \$600 million 144A convertible note financing.
- General counsel to satellite broadband company, including advising on its \$1+ billion equity financing led by SoftBank.
- **Datawatch Corporation's** (*Nasdaq: DWCH*) \$176 million merger with Altair Engineering (*Nasdaq: ALTR*).
- **Examity Inc.'s** \$90 million growth equity investment from private equity firm Great Hill Partners.
- **BioRx's** \$350 million sale to Diplomat Pharmacy (*NYSE: DPLO*).

- **Cyteir Therapeutics'** equity financing led by Venrock Partners, Celgene, Lightstone Ventures, and DROIA Oncology Venture.
- **Cosman Medical's** sale to Boston Scientific (*NYSE: BSX*).
- FP Resources USA Inc.'s take-private acquisition of **The First Marblehead Corporation** (*NYSE: FMD*).
- **Datawatch Corporation's** (*NASDAQ: DWCH*) acquisition of Angoss Software Corporation.

PUBLICATIONS AND PRESENTATIONS

- "Funding Gap for Life Sciences Companies is Still a Problem," *co-author, Life Sciences Law360*.

PROFESSIONAL AND COMMUNITY INVOLVEMENT

- Corporate pro bono work for the Center for Women & Enterprise
- Pro bono clients from the Lawyer's Clearinghouse and Massachusetts Legal Clinic for the Homeless
- Member of the Boston Bar and American Bar Associations
- Member of Choate's Hiring Committee